Puma Biotechnology Inc Dossier - Source-backed chat

Puma Biotechnology Inc

PBYINASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.15

Intrinsic Value $3.46median of 3 methodsbased on filings through 30 Jun 2026

Market Price $9.84Price as of 1 Oct 2026

Significantly overvaluedIntrinsic value is 65% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (-65%)

Data confidence Sign in to view data confidence

Market Cap $507.9M

Enterprise Value $471.4M

Shares Outstanding 52.9M diluted

Moat Rating Wide

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Puma Biotechnology is in a transition phase, balancing the commercialization of its sole marketed product, NERLYNX, with the clinical development of its in-licensed pipeline asset, alisertib. While Q1 2026 financial results exceeded conservative guidance and prompted management to raise full-year 2026 revenue and net income outlooks, the long-term growth trajectory remains constrained by the mature market and competitive headwinds facing NERLYNX. Increased R&D spending on alisertib Phase II trials (ALISCA-Breast1 and ALISCA-Lung1) will continue to compress near-term margins, making upcoming clinical readouts the primary catalysts for the stock.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$6.00

Mean target$6.00

High · most bullish analyst$6.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

NERLYNX sales experience a sharper-than-expected decline due to intense competitive pressures in the HER2-positive breast cancer market and faster-than-anticipated market maturity. Concurrently, alisertib clinical trials encounter safety concerns or fail to show meaningful efficacy, leading to pipeline delays or write-downs. Increased R&D burn combined with falling revenues erodes the company's cash position and eliminates profitability.

Base CaseCentral scenario

NERLYNX sales stabilize within the raised guidance range of $202M to $206M for FY 2026, supported by steady demand and international partnerships. Alisertib Phase II trials progress as planned with enrollment expansions in H2 2026 and updated data presentations in Q4 2026, keeping the pipeline on track without major safety or efficacy setbacks. Profitability is maintained with full-year net income reaching the guided $16M to $19M range.

Bull CaseUpside scenario

The bull case for Puma Biotechnology hinges on its underlying value, strong cash generation from its core asset, and pipeline potential. Despite conservative guidance for 2026, the company's Q4 2025 performance demonstrated robust execution with Nerlynx product revenues growing 10% year-over-year and royalty revenues surging 232%. This core business continues to generate significant cash flow, allowing Puma to end 2025 with $97.5 million in cash and investments and a reduced debt load of $22 million. This financial stability provides a solid foundation to weather near-term dips while funding the clinical development of its promising pipeline asset, alisertib (an aurora kinase A inhibitor), which is currently in mid-stage trials for hormone receptor-positive breast cancer and small-cell lung cancer.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Raised FY 2026 guidance reflecting resilient underlying demand for NERLYNX.
Debt-free balance sheet with $101.5 million in cash, cash equivalents, and marketable securities as of March 31, 2026.
Strategic focus on biomarker-directed clinical development for alisertib, which could accelerate regulatory timelines.

Key Investment Risks

High concentration risk with total revenue heavily dependent on a single commercial product (NERLYNX).
Rising R&D expenses associated with advancing alisertib trials, which will compress operating margins.
Intense competition in the oncology space from larger, better-capitalized pharmaceutical companies.

Thesis Invalidation Triggers

A significant drop in NERLYNX new patient starts or rapid market share loss to competitors.
Failure of alisertib to meet efficacy endpoints or the emergence of severe adverse safety signals in Phase II trials.
A material increase in operating cash burn that threatens the company's multi-year cash runway.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.